In Friday’s Wall Street session, FibroGen Inc (NASDAQ:FGEN) shares traded at $0.33, up 0.46% from the previous session.
FGEN stock price is now 4.27% away from the 50-day moving average and -16.76% away from the 200-day moving average. The market capitalization of the company currently stands at $33.34M.
With the price target reduced from $4 to $2, BofA Securities Downgraded its rating from Neutral to Underperform for FibroGen Inc (NASDAQ: FGEN). , while ‘Stifel’ rates the stock as ‘Hold’
In other news, Wettig Thane, CEO bought 145,000 shares of the company’s stock on Mar 24 ’25. The stock was bought for $50,663 at an average price of $0.35. Upon completion of the transaction, the CEO now directly owns 543,329 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 20 ’25, Director Schoeneck James A bought 250,000 shares of the business’s stock. A total of $88,000 was incurred on buying the stock at an average price of $0.35. This leaves the insider owning 323,722 shares of the company worth $0.11 million. A total of 6.90% of the company’s stock is owned by insiders.
During the past 12 months, FibroGen Inc has had a low of $0.18 and a high of $1.53.
The company reported revenue of $2.74 million for the quarter, compared to $25.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -89.2 percent. For the current quarter, analysts expect FGEN to generate $2.88M in revenue.
